Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Capecitabine in Treating Patients With Malignant Mesothelioma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology Identifier:
First received: January 21, 2000
Last updated: July 12, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2006
  Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Otterson GA, Herndon J, Watson D, et al.: Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 39807). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2778, 691, 2003.